1. Cooper BA, Branley P, Bulfone L, et al. A randomized, controlled trial of early versus late initiation of dialysis.
N Engl J Med 2010;363:609–619.
2. Collins J, Cooper B, Branley P, et al. Outcomes of patients with planned initiation of hemodialysis in the IDEAL trial.
Contrib Nephrol 2011;171:1–9.
3. Harris A, Cooper BA, Li JJ, et al. Cost-effectiveness of initiating dialysis early: a randomized controlled trial.
Am J Kidney Dis 2011;57:707–715.
4. Whalley GA, Marwick TH, Doughty RN, et al. Effect of early initiation of dialysis on cardiac structure and function: results from the echo substudy of the IDEAL trial.
Am J Kidney Dis 2013;61:262–270.
5. Korevaar JC, Jansen MA, Dekker FW, et al. When to initiate dialysis: effect of proposed US guidelines on survival.
Lancet 2001;358:1046–1050.
6. Traynor JP, Simpson K, Geddes CC, Deighan CJ, Fox JG. Early initiation of dialysis fails to prolong survival in patients with end-stage renal failure.
J Am Soc Nephrol 2002;13:2125–2132.
7. Kazmi WH, Gilbertson DT, Obrador GT, et al. Effect of comorbidity on the increased mortality associated with early initiation of dialysis.
Am J Kidney Dis 2005;46:887–896.
8. Hwang SJ, Yang WC, Lin MY, Mau LW, Chen HC; Taiwan Society of Nephrology. Impact of the clinical conditions at dialysis initiation on mortality in incident haemodialysis patients: a national cohort study in Taiwan.
Nephrol Dial Transplant 2010;25:2616–2624.
9. Lassalle M, Labeeuw M, Frimat L, et al. Age and comorbidity may explain the paradoxical association of an early dialysis start with poor survival.
Kidney Int 2010;77:700–707.
10. Wright S, Klausner D, Baird B, et al. Timing of dialysis initiation and survival in ESRD.
Clin J Am Soc Nephrol 2010;5:1828–1835.
11. Clark WF, Na Y, Rosansky SJ, et al. Association between estimated glomerular filtration rate at initiation of dialysis and mortality.
CMAJ 2011;183:47–53.
12. Chang JH, Rim MY, Sung J, et al. Early start of dialysis has no survival benefit in end-stage renal disease patients.
J Korean Med Sci 2012;27:1177–1181.
13. Zhang Y, Hu C, Bian Z, Chen P. Impact of timing of initiation of dialysis on long-term prognosis of patients undergoing hemodialysis.
Exp Ther Med 2018;16:1209–1215.
14. Susantitaphong P, Altamimi S, Ashkar M, et al. GFR at initiation of dialysis and mortality in CKD: a meta-analysis.
Am J Kidney Dis 2012;59:829–840.
15. Kim DH, Park JI, Lee JP, et al. The effects of vascular access types on the survival and quality of life and depression in the incident hemodialysis patients.
Ren Fail 2020;42:30–39.
16. Ozeki T, Shimizu H, Fujita Y, et al. The type of vascular access and the incidence of mortality in Japanese dialysis patients.
Intern Med 2017;56:481–485.
17. Bae E, Lee H, Kim DK, et al. Autologous arteriovenous fistula is associated with superior outcomes in elderly hemodialysis patients.
BMC Nephrol 2018;19:306.
18. Yeh LM, Chiu SY, Lai PC. The impact of vascular access types on hemodialysis patient long-term survival.
Sci Rep 2019;9:10708.
19. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 update.
Am J Kidney Dis 2020;75(4 Suppl 2):S1–S164.
20. Shechter SM, Skandari MR, Zalunardo N. Timing of arteriovenous fistula creation in patients with CKD: a decision analysis.
Am J Kidney Dis 2014;63:95–103.
21. Locham S, Naazie I, Canner J, Siracuse J, Al-Nouri O, Malas M. Incidence and risk factors of sepsis in hemodialysis patients in the United States.
J Vasc Surg 2021;73:1016–1021.
22. Miyamoto M, Kurita N, Suemitsu K, Murakami M. Fistula and survival outcomes after fistula creation among predialysis chronic kidney disease stage 5 patients.
Am J Nephrol 2017;45:356–364.
23. Leermakers JJ, Bode AS, Vaidya A, van der Sande FM, Evers SM, Tordoir JH. Cost-effectiveness of vascular access for haemodialysis: arteriovenous fistulas versus arteriovenous grafts.
Eur J Vasc Endovasc Surg 2013;45:84–92.
24. Hall RK, Myers ER, Rosas SE, O’Hare AM, Colón-Emeric CS. Choice of hemodialysis access in older adults: a cost-effectiveness analysis.
Clin J Am Soc Nephrol 2017;12:947–954.
25. Dember LM, Lacson E Jr, Brunelli SM, et al. The TiME trial: a fully embedded, cluster-randomized, pragmatic trial of hemodialysis session duration.
J Am Soc Nephrol 2019;30:890–903.
26. Lowrie EG, Laird NM, Parker TF, Sargent JA. Effect of the hemodialysis prescription of patient morbidity: report from the National Cooperative Dialysis Study.
N Engl J Med 1981;305:1176–1181.
27. Brunelli SM, Chertow GM, Ankers ED, Lowrie EG, Thadhani R. Shorter dialysis times are associated with higher mortality among incident hemodialysis patients.
Kidney Int 2010;77:630–636.
28. Flythe JE, Curhan GC, Brunelli SM. Shorter length dialysis sessions are associated with increased mortality, independent of body weight.
Kidney Int 2013;83:104–113.
29. Shinzato T, Nakai S, Akiba T, et al. Survival in long-term haemodialysis patients: results from the annual survey of the Japanese Society for Dialysis Therapy.
Nephrol Dial Transplant 1997;12:884–888.
30. Tentori F, Zhang J, Li Y, et al. Longer dialysis session length is associated with better intermediate outcomes and survival among patients on in-center three times per week hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).
Nephrol Dial Transplant 2012;27:4180–4188.
31. Shemin D, Bostom AG, Laliberty P, Dworkin LD. Residual renal function and mortality risk in hemodialysis patients.
Am J Kidney Dis 2001;38:85–90.
32. Charra B, Calemard M, Laurent G. Importance of treatment time and blood pressure control in achieving long-term survival on dialysis.
Am J Nephrol 1996;16:35–44.
33. Marshall MR, Byrne BG, Kerr PG, McDonald SP. Associations of hemodialysis dose and session length with mortality risk in Australian and New Zealand patients.
Kidney Int 2006;69:1229–1236.
34. Hwang HS, Hong YA, Yoon HE, et al. Comparison of clinical outcome between twice-weekly and thrice-weekly hemodialysis in patients with residual kidney function.
Medicine (Baltimore) 2016;95:e2767.
35. Lin X, Gu L, Zhu M, et al. Clinical outcome of twice-weekly hemodialysis patients with long-term dialysis vintage.
Kidney Blood Press Res 2018;43:1104–1112.
36. Sun Y, Wang Y, Yu W, Zhuo Y, Yuan Q, Wu X. Association of dose and frequency on the survival of patients on maintenance of hemodialysis in China: a Kaplan-Meier and Cox-proportional hazard model analysis.
Med Sci Monit 2018;24:5329–5337.
37. Obi Y, Eriguchi R, Ou SM, Rhee CM, Kalantar-Zadeh K. What is known and unknown about twice-weekly hemodialysis.
Blood Purif 2015;40:298–305.
38. Vanholder R, Van Biesen W, Lameire N. Is starting hemodialysis on a twice-weekly regimen a valid option?
Am J Kidney Dis 2014;64:165–167.
39. Held PJ, Port FK, Wolfe RA, et al. The dose of hemodialysis and patient mortality.
Kidney Int 1996;50:550–556.
40. Bloembergen WE, Stannard DC, Port FK, et al. Relationship of dose of hemodialysis and cause-specific mortality.
Kidney Int 1996;50:557–565.
41. Chertow GM, Owen WF, Lazarus JM, Lew NL, Lowrie EG. Exploring the reverse J-shaped curve between urea reduction ratio and mortality.
Kidney Int 1999;56:1872–1878.
42. Wolfe RA, Ashby VB, Daugirdas JT, Agodoa LY, Jones CA, Port FK. Body size, dose of hemodialysis, and mortality.
Am J Kidney Dis 2000;35:80–88.
43. Port FK, Ashby VB, Dhingra RK, Roys EC, Wolfe RA. Dialysis dose and body mass index are strongly associated with survival in hemodialysis patients.
J Am Soc Nephrol 2002;13:1061–1066.
44. Salahudeen AK, Dykes P, May W. Risk factors for higher mortality at the highest levels of spKt/V in haemodialysis patients.
Nephrol Dial Transplant 2003;18:1339–1344.
45. Termorshuizen F, Dekker FW, van Manen JG, et al. Relative contribution of residual renal function and different measures of adequacy to survival in hemodialysis patients: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2.
J Am Soc Nephrol 2004;15:1061–1070.
46. Port FK, Wolfe RA, Hulbert-Shearon TE, McCullough KP, Ashby VB, Held PJ. High dialysis dose is associated with lower mortality among women but not among men.
Am J Kidney Dis 2004;43:1014–1023.
47. Ramirez SP, Kapke A, Port FK, et al. Dialysis dose scaled to body surface area and size-adjusted, sex-specific patient mortality.
Clin J Am Soc Nephrol 2012;7:1977–1987.
48. Hong WP, Lee YJ. The association of dialysis adequacy, body mass index, and mortality among hemodialysis patients.
BMC Nephrol 2019;20:382.
49. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis.
N Engl J Med 2002;347:2010–2019.
50. Daugirdas JT, Depner TA, Gotch FA, et al. Comparison of methods to predict equilibrated Kt/V in the HEMO Pilot Study.
Kidney Int 1997;52:1395–1405.
51. Daugirdas JT, Depner TA, Greene T, et al. Standard Kt/Vurea: a method of calculation that includes effects of fluid removal and residual kidney clearance.
Kidney Int 2010;77:637–644.
52. Pattharanitima P, Chauhan K, El Shamy O, et al. The association of standard Kt/V and surface area-normalized standard Kt/V with clinical outcomes in hemodialysis patients.
Hemodial Int 2020;24:495–505.
53. Rivara MB, Ravel V, Streja E, et al. Weekly standard Kt/Vurea and clinical outcomes in home and in-center hemodialysis.
Clin J Am Soc Nephrol 2018;13:445–455.
54. Locatelli F, Martin-Malo A, Hannedouche T, et al. Effect of membrane permeability on survival of hemodialysis patients.
J Am Soc Nephrol 2009;20:645–654.
55. Asci G, Tz H, Ozkahya M, et al. The impact of membrane permeability and dialysate purity on cardiovascular outcomes.
J Am Soc Nephrol 2013;24:1014–1023.
56. Ayli M, Ayli D, Azak A, et al. The effect of high-flux hemodialysis on dialysis-associated amyloidosis.
Ren Fail 2005;27:31–34.
57. Chazot C, Kirchgessner J, Pham J, et al. Effect of membrane permeability on cardiovascular risk factors and β
2m plasma levels in patients on long-term haemodialysis: a randomised crossover trial.
Nephron 2015;129:269–275.
58. Klemm A, Franke C, Busch M, et al. Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites.
Clin Nephrol 2004;61:191–197.
59. Küchle C, Fricke H, Held E, Schiffl H. High-flux hemodialysis postpones clinical manifestation of dialysis-related amyloidosis.
Am J Nephrol 1996;16:484–488.
60. Lang SM, Bergner A, Töpfer M, Schiffl H. Preservation of residual renal function in dialysis patients: effects of dialysis-technique-related factors.
Perit Dial Int 2001;21:52–57.
61. Li PK, Cheng YL, Leung CB, et al. Effect of membrane permeability on inflammation and arterial stiffness: a randomized trial.
Clin J Am Soc Nephrol 2010;5:652–658.
62. Locatelli F, Andrulli S, Pecchini F, et al. Effect of high-flux dialysis on the anaemia of haemodialysis patients.
Nephrol Dial Transplant 2000;15:1399–1409.
63. Locatelli F, Mastrangelo F, Redaelli B, et al. Effects of different membranes and dialysis technologies on patient treatment tolerance and nutritional parameters. The Italian Cooperative Dialysis Study Group.
Kidney Int 1996;50:1293–1302.
64. Simon P, Ang KS, Cam G, Benziane A, Bonn F. Indices of adequate dialysis in patients hemodialyzed with AN 69 membrane.
Kidney Int Suppl 1993;41:S291–S295.
65. Ok E, Asci G, Toz H, et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study.
Nephrol Dial Transplant 2013;28:192–202.
66. Morena M, Jaussent A, Chalabi L, et al. Treatment tolerance and patient-reported outcomes favor online hemodiafiltration compared to high-flux hemodialysis in the elderly.
Kidney Int 2017;91:1495–1509.
67. Maduell F, Moreso F, Pons M, et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients.
J Am Soc Nephrol 2013;24:487–497.
68. Suwabe T, Barrera-Flores FJ, Rodriguez-Gutierrez R, Ubara Y, Takaichi K. Effect of online hemodiafiltration compared with hemodialysis on quality of life in patients with ESRD: a systematic review and meta-analysis of randomized trials.
PLoS One 2018;13:e0205037.
69. Kantartzi K, Panagoutsos S, Mourvati E, et al. Can dialysis modality influence quality of life in chronic hemodialysis patients?: low-flux hemodialysis versus high-flux hemodiafiltration: a cross-over study.
Ren Fail 2013;35:216–221.
70. Karkar A, Abdelrahman M, Locatelli F. A randomized trial on health-related patient satisfaction level with high-efficiency online hemodiafiltration versus high-flux dialysis.
Blood Purif 2015;40:84–91.
71. Mazairac AH, de Wit GA, Grooteman MP, et al. Effect of hemodiafiltration on quality of life over time.
Clin J Am Soc Nephrol 2013;8:82–89.
72. Smith JR, Zimmer N, Bell E, Francq BG, McConnachie A, Mactier R. A randomized, single-blind, crossover trial of recovery time in high-flux hemodialysis and hemodiafiltration.
Am J Kidney Dis 2017;69:762–770.
73. Ward RA, Schmidt B, Hullin J, Hillebrand GF, Samtleben W. A comparison of on-line hemodiafiltration and high-flux hemodialysis: a prospective clinical study.
J Am Soc Nephrol 2000;11:2344–2350.
74. Nistor I, Palmer SC, Craig JC, et al. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease.
Cochrane Database Syst Rev 2015;(5):CD006258.
75. National Kidney Foundation. KDOQI Clinical Practice Guideline for Hemodialysis Adequacy: 2015 update.
Am J Kidney Dis 2015;66:884–930.
76. Nistor I, Palmer SC, Craig JC, et al. Convective versus diffusive dialysis therapies for chronic kidney failure: an updated systematic review of randomized controlled trials.
Am J Kidney Dis 2014;63:954–967.
78. Ashby D, Borman N, Burton J, et al. Renal Association Clinical Practice Guideline on Haemodialysis.
BMC Nephrol 2019;20:379.
79. Lazrak HH, René É, Elftouh N, Leblanc M, Lafrance JP. Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis.
BMC Nephrol 2017;18:187.
80. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials.
J Am Soc Nephrol 2004;15:3192–3206.
81. Palamaner Subash Shantha G, Kumar AA, Sethi M, Khanna RC, Pancholy SB. Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis.
PeerJ 2015;3:e835.
82. Borm JJ, Krediet R, Sturk A, ten Cate JW. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study.
Haemostasis 1986;16 Suppl 2:59–68.
83. Koutsikos D, Fourtounas C, Kapetanaki A, et al. A cross-over study of a new low molecular weight heparin (Logiparin) in hemodialysis.
Int J Artif Organs 1996;19:467–471.
84. Ryan KE, Lane DA, Flynn A, Shepperd J, Ireland HA, Curtis JR. Dose finding study of a low molecular weight heparin, Innohep, in haemodialysis.
Thromb Haemost 1991;66:277–282.
85. Al-Saran KA, Sabry A, Taha M, Ghafour MA, Al Fawzan F. Profile of low molecular weight tinzaparin sodium for anticoagulation during hemodialysis.
Saudi J Kidney Dis Transpl 2010;21:43–49.
86. Bramham K, Varrier M, Asgari E, Makanjuola D. Comparison of Tinzaparin and unfractionated heparin as anticoagulation on haemodialysis: equal safety, efficacy and economical parity.
Nephron Clin Pract 2008;110:c107–c113.
87. Yang C, Wu T, Huang C. Low molecular weight heparin reduces triglyceride, VLDL and cholesterol/HDL levels in hyperlipidemic diabetic patients on hemodialysis.
Am J Nephrol 1998;18:384–390.
88. Sabry A, Taha M, Nada M, Al Fawzan F, Alsaran K. Anticoagulation therapy during haemodialysis: a comparative study between two heparin regimens.
Blood Coagul Fibrinolysis 2009;20:57–62.
89. Bambauer R, Rücker S, Weber U, Köhler M. Comparison of low molecular weight heparin and standard heparin in hemodialysis.
ASAIO Trans 1990;36:M646–M649.
90. Lord H, Jean N, Dumont M, Kassis J, Leblanc M. Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center.
Am J Nephrol 2002;22:58–66.
91. Nurmohamed MT, ten Cate J, Stevens P, Hoek JA, Lins RL, ten Cate JW. Long-term efficacy and safety of a low molecular weight heparin in chronic hemodialysis patients: a comparison with standard heparin.
ASAIO Trans 1991;37:M459–M461.
92. Saltissi D, Morgan C, Westhuyzen J, Healy H. Comparison of low-molecular-weight heparin (enoxaparin sodium) and standard unfractionated heparin for haemodialysis anticoagulation.
Nephrol Dial Transplant 1999;14:2698–2703.
93. Schrader J, Stibbe W, Armstrong VW, et al. Comparison of low molecular weight heparin to standard heparin in hemodialysis/hemofiltration.
Kidney Int 1988;33:890–896.
94. Stefoni S, Cianciolo G, Donati G, et al. Standard heparin versus low-molecular-weight heparin: a medium-term comparison in hemodialysis.
Nephron 2002;92:589–600.
95. Kim HC, Han SY, Kim HK, et al. A multi-center phase III clinical trial to assess the influence to bleeding and anticoagulant effect of nafamostat mesilate (Futhan) in hemodialysis patients with high bleeding-risk. Korean J Nephrol 2004;23:920–926.
96. Yang JW, Han BG, Kim BR, et al. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage.
Ren Fail 2009;31:668–675.
97. Akizawa T, Koshikawa S, Ota K, Kazama M, Mimura N, Hirasawa Y. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding.
Nephron 1993;64:376–381.
98. Sahota S, Rodby R. Inpatient hemodialysis without anticoagulation in adults.
Clin Kidney J 2014;7:552–556.
99. Guéry B, Alberti C, Servais A, et al. Hemodialysis without systemic anticoagulation: a prospective randomized trial to evaluate 3 strategies in patients at risk of bleeding.
PLoS One 2014;9:e97187.
100. Lavaud S, Paris B, Maheut H, et al. Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration.
ASAIO J 2005;51:348–351.
101. Laville M, Dorval M, Fort Ros J, et al. Results of the HepZero study comparing heparin-grafted membrane and standard care show that heparin-grafted dialyzer is safe and easy to use for heparin-free dialysis.
Kidney Int 2014;86:1260–1267.
102. Kreuzer M, Bonzel KE, Büscher R, Offner G, Ehrich JH, Pape L. Regional citrate anticoagulation is safe in intermittent high-flux haemodialysis treatment of children and adolescents with an increased risk of bleeding.
Nephrol Dial Transplant 2010;25:3337–3342.
103. Swartz RD, Flamenbaum W, Dubrow A, Hall JC, Crow JW, Cato A. Epoprostenol (PGI2, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications.
J Clin Pharmacol 1988;28:818–825.
104. Kalantar-Zadeh K, Regidor DL, Kovesdy CP, et al. Fluid retention is associated with cardiovascular mortality in patients undergoing long-term hemodialysis.
Circulation 2009;119:671–679.
105. Stegmayr BG, Brannstrom M, Bucht S, et al. Minimized weight gain between hemodialysis contributes to a reduced risk of death.
Int J Artif Organs 2006;29:675–680.
106. Foley RN, Herzog CA, Collins AJ; United States Renal Data System. Blood pressure and long-term mortality in United States hemodialysis patients: USRDS Waves 3 and 4 Study.
Kidney Int 2002;62:1784–1790.
107. Saran R, Bragg-Gresham JL, Rayner HC, et al. Nonadherence in hemodialysis: associations with mortality, hospitalization, and practice patterns in the DOPPS.
Kidney Int 2003;64:254–262.
108. Hecking M, Moissl U, Genser B, et al. Greater fluid overload and lower interdialytic weight gain are independently associated with mortality in a large international hemodialysis population.
Nephrol Dial Transplant 2018;33:1832–1842.
109. Kurita N, Hayashino Y, Yamazaki S, et al. Revisiting interdialytic weight gain and mortality association with serum albumin interactions: the Japanese Dialysis Outcomes and Practice Pattern Study.
J Ren Nutr 2017;27:421–429.
110. Toida T, Iwakiri T, Sato Y, Komatsu H, Kitamura K, Fujimoto S. Relationship between hemoglobin levels corrected by interdialytic weight gain and mortality in Japanese hemodialysis patients: Miyazaki Dialysis Cohort Study.
PLoS One 2017;12:e0169117.
111. Lee MJ, Doh FM, Kim CH, et al. Interdialytic weight gain and cardiovascular outcome in incident hemodialysis patients.
Am J Nephrol 2014;39:427–435.
112. Stefánsson BV, Brunelli SM, Cabrera C, et al. Intradialytic hypotension and risk of cardiovascular disease.
Clin J Am Soc Nephrol 2014;9:2124–2132.
113. Wong MM, McCullough KP, Bieber BA, et al. Interdialytic weight gain: trends, predictors, and associated outcomes in the International Dialysis Outcomes and Practice Patterns Study (DOPPS).
Am J Kidney Dis 2017;69:367–379.
114. Dantas LG, de Seixas Rocha M, Junior JA, Paschoalin EL, Paschoalin SR, Sampaio Cruz CM. Non-adherence to haemodialysis, interdialytic weight gain and cardiovascular mortality: a cohort study.
BMC Nephrol 2019;20:402.
115. Leggat JE Jr, Orzol SM, Hulbert-Shearon TE, et al. Noncompliance in hemodialysis: predictors and survival analysis.
Am J Kidney Dis 1998;32:139–145.
116. Watanabe Y, Yamagata K, Nishi S, et al. Japanese Society for Dialysis Therapy clinical guideline for “hemodialysis initiation for maintenance hemodialysis”.
Ther Apher Dial 2015;19 Suppl 1:93–107.
117. Flythe JE, Kimmel SE, Brunelli SM. Rapid fluid removal during dialysis is associated with cardiovascular morbidity and mortality.
Kidney Int 2011;79:250–257.
118. Saran R, Bragg-Gresham JL, Levin NW, et al. Longer treatment time and slower ultrafiltration in hemodialysis: associations with reduced mortality in the DOPPS.
Kidney Int 2006;69:1222–1228.
119. Hecking M, Karaboyas A, Antlanger M, et al. Significance of interdialytic weight gain versus chronic volume overload: consensus opinion.
Am J Nephrol 2013;38:78–90.
120. Dunlop JL, Vandal AC, de Zoysa JR, et al. Rationale and design of the Sodium Lowering In Dialysate (SoLID) trial: a randomised controlled trial of low versus standard dialysate sodium concentration during hemodialysis for regression of left ventricular mass.
BMC Nephrol 2013;14:149.
121. Charra B, Calemard E, Ruffet M, et al. Survival as an index of adequacy of dialysis.
Kidney Int 1992;41:1286–1291.
122. London GM, Pannier B, Guerin AP, et al. Alterations of left ventricular hypertrophy in and survival of patients receiving hemodialysis: follow-up of an interventional study.
J Am Soc Nephrol 2001;12:2759–2767.
123. Mominadam S, Ozkahya M, Kayikcioglu M, et al. Interdialytic blood pressure obtained by ambulatory blood pressure measurement and left ventricular structure in hypertensive hemodialysis patients.
Hemodial Int 2008;12:322–327.
124. FHN Trial Group, Chertow GM, Levin NW, et al. In-center hemodialysis six times per week versus three times per week.
N Engl J Med 2010;363:2287–2300.
125. Culleton BF, Walsh M, Klarenbach SW, et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial.
JAMA 2007;298:1291–1299.
126. Katzarski KS, Charra B, Luik AJ, et al. Fluid state and blood pressure control in patients treated with long and short haemodialysis.
Nephrol Dial Transplant 1999;14:369–375.
127. Wald R, Yan AT, Perl J, et al. Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis.
BMC Nephrol 2012;13:3.
128. Chan CT, Floras JS, Miller JA, Richardson RM, Pierratos A. Regression of left ventricular hypertrophy after conversion to nocturnal hemodialysis.
Kidney Int 2002;61:2235–2239.
129. Marshall MR, Dunlop JL. Are dialysate sodium levels too high?
Semin Dial 2012;25:277–283.
130. Kim SM, Kim JG, Shin JH, et al. The effects of low sodium dialysate in hemodialysis patients. Korean J Nephrol 2011;30:53–60.
131. Dunlop JL, Vandal AC, Marshall MR. Low dialysate sodium levels for chronic haemodialysis.
Cochrane Database Syst Rev 2019;1:CD011204.
132. Beduschi GC, Telini LS, Caramori JC, Martin LC, Barretti P. Effect of dialysate sodium reduction on body water volume, blood pressure, and inflammatory markers in hemodialysis patients: a prospective randomized controlled study.
Ren Fail 2013;35:742–747.
133. Boquin E, Parnell S, Grondin G, et al. Crossover study of the effects of different dialysate sodium concentrations in large surface area, short-term dialysis.
Proc Clin Dial Transplant Forum 1977;7:48–52.
134. Liu J, Sun F, Ma LJ, Shen Y, Mei X, Zhou YL. Increasing dialysis sodium removal on arterial stiffness and left ventricular hypertrophy in hemodialysis patients.
J Ren Nutr 2016;26:38–44.
135. Akyol A, Akdag S, Asker M, et al. Effects of lowered dialysate sodium on left ventricle function and brain natriuretic peptide in maintenance of hemodialysis patients.
Hum Exp Toxicol 2017;36:128–134.
136. Arramreddy R, Sun SJ, Munoz Mendoza J, Chertow GM, Schiller B. Individualized reduction in dialysate sodium in conventional in-center hemodialysis.
Hemodial Int 2012;16:473–480.
137. Kooman JP, Hendriks EJ, van Den Sande FM, Leumissen KM. Dialysate sodium concentration and blood pressure control in haemodialysis patients.
Nephrol Dial Transplant 2000;15:554.
138. Sayarlioglu H, Erkoc R, Tuncer M, et al. Effects of low sodium dialysate in chronic hemodialysis patients: an echocardiographic study.
Ren Fail 2007;29:143–146.
139. Zhou YL, Liu J, Ma LJ, et al. Effects of increasing diffusive sodium removal on blood pressure control in hemodialysis patients with optimal dry weight.
Blood Purif 2013;35:209–215.
140. Amro A, Waldum B, Dammen T, Miaskowski C, Os I. Symptom clusters in patients on dialysis and their association with quality-of-life outcomes.
J Ren Care 2014;40:23–33.
141. Caplin B, Kumar S, Davenport A. Patients’ perspective of haemodialysis-associated symptoms.
Nephrol Dial Transplant 2011;26:2656–2663.
142. Heerspink HJ, Ninomiya T, Zoungas S, et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials.
Lancet 2009;373:1009–1015.
143. Hannedouche T, Roth H, Krummel T, et al. Multiphasic effects of blood pressure on survival in hemodialysis patients.
Kidney Int 2016;90:674–684.
144. Jhee JH, Park J, Kim H, et al. The optimal blood pressure target in different dialysis populations.
Sci Rep 2018;8:14123.
145. Van Buren PN, Kim C, Toto R, Inrig JK. Intradialytic hypertension and the association with interdialytic ambulatory blood pressure.
Clin J Am Soc Nephrol 2011;6:1684–1691.
146. Assimon MM, Brookhart MA, Fine JP, Heiss G, Layton JB, Flythe JE. A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis.
Am J Kidney Dis 2018;72:337–348.
147. Agarwal R, Alborzi P, Satyan S, Light RP. Dry-weight reduction in hypertensive hemodialysis patients (DRIP): a randomized, controlled trial.
Hypertension 2009;53:500–507.
148. Zhang H, Preciado P, Wang Y, et al. Association of all-cause mortality with predialysis systolic blood pressure and its peridialytic change in chronic hemodialysis patients.
Nephrol Dial Transplant 2020;35:1602–1608.
149. Alborzi P, Patel N, Agarwal R. Home blood pressures are of greater prognostic value than hemodialysis unit recordings.
Clin J Am Soc Nephrol 2007;2:1228–1234.
150. Agarwal R, Peixoto AJ, Santos SF, Zoccali C. Pre- and postdialysis blood pressures are imprecise estimates of interdialytic ambulatory blood pressure.
Clin J Am Soc Nephrol 2006;1:389–398.
151. Tsujimoto Y, Tsujimoto H, Nakata Y, et al. Dialysate temperature reduction for intradialytic hypotension for people with chronic kidney disease requiring haemodialysis.
Cochrane Database Syst Rev 2019;7:CD012598.
152. Selby NM, Burton JO, Chesterton LJ, McIntyre CW. Dialysis-induced regional left ventricular dysfunction is ameliorated by cooling the dialysate.
Clin J Am Soc Nephrol 2006;1:1216–1225.
153. Chesterton LJ, Selby NM, Burton JO, McIntyre CW. Cool dialysate reduces asymptomatic intradialytic hypotension and increases baroreflex variability.
Hemodial Int 2009;13:189–196.
154. Fine A, Penner B. The protective effect of cool dialysate is dependent on patients’ predialysis temperature.
Am J Kidney Dis 1996;28:262–265.
155. Jost CM, Agarwal R, Khair-el-Din T, Grayburn PA, Victor RG, Henrich WL. Effects of cooler temperature dialysate on hemodynamic stability in “problem” dialysis patients.
Kidney Int 1993;44:606–612.
156. Ayoub A, Finlayson M. Effect of cool temperature dialysate on the quality and patients’ perception of haemodialysis.
Nephrol Dial Transplant 2004;19:190–194.
157. Maggiore Q, Pizzarelli F, Santoro A, et al. The effects of control of thermal balance on vascular stability in hemodialysis patients: results of the European randomized clinical trial.
Am J Kidney Dis 2002;40:280–290.
158. Jefferies HJ, Burton JO, McIntyre CW. Individualised dialysate temperature improves intradialytic haemodynamics and abrogates haemodialysis-induced myocardial stunning, without compromising tolerability.
Blood Purif 2011;32:63–68.
159. Cruz DN, Mahnensmith RL, Brickel HM, Perazella MA. Midodrine and cool dialysate are effective therapies for symptomatic intradialytic hypotension.
Am J Kidney Dis 1999;33:920–926.
160. Azar AT. Effect of dialysate temperature on hemodynamic stability among hemodialysis patients.
Saudi J Kidney Dis Transpl 2009;20:596–603.
161. Hegbrant J, Thysell H, Mårtensson L, Nielsen AL, Lindberg BF. Delayed decrease in plasma levels of atrial natriuretic peptide during cold hemodialysis.
Nephron 1994;68:427–432.
162. Selby NM, McIntyre CW. A systematic review of the clinical effects of reducing dialysate fluid temperature.
Nephrol Dial Transplant 2006;21:1883–1898.
163. Mustafa RA, Bdair F, Akl EA, et al. Effect of lowering the dialysate temperature in chronic hemodialysis: a systematic review and meta-analysis.
Clin J Am Soc Nephrol 2016;11:442–457.
164. Owen WF Jr, Lew NL, Liu Y, Lowrie EG, Lazarus JM. The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis.
N Engl J Med 1993;329:1001–1006.
165. Hakim RM, Breyer J, Ismail N, Schulman G. Effects of dose of dialysis on morbidity and mortality.
Am J Kidney Dis 1994;23:661–669.
166. Parker TF 3rd, Husni L, Huang W, Lew N, Lowrie EG. Survival of hemodialysis patients in the United States is improved with a greater quantity of dialysis.
Am J Kidney Dis 1994;23:670–680.
167. Collins AJ, Ma JZ, Umen A, Keshaviah P. Urea index and other predictors of hemodialysis patient survival.
Am J Kidney Dis 1994;23:272–282.
168. Thomas A, Silver SA, Perl J, et al. The frequency of routine blood sampling and patient outcomes among maintenance hemodialysis recipients.
Am J Kidney Dis 2020;75:471–479.
169. Hemodialysis Adequacy 2006 Work Group. Clinical practice guidelines for hemodialysis adequacy, update 2006.
Am J Kidney Dis 2006;48 Suppl 1:S2–S90.
170. Tattersall J, Martin-Malo A, Pedrini L, et al. EBPG guideline on dialysis strategies.
Nephrol Dial Transplant 2007;22 Suppl 2:ii5–ii21.
171. Drüeke TB, Parfrey PS. Summary of the KDIGO guideline on anemia and comment: reading between the (guide)line(s).
Kidney Int 2012;82:952–960.
172. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Grou. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009;113:S1–S130.
173. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD).
Kidney Int Suppl (2011) 2017;7:1–59.
174. Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C Work Group. KDIGO 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.
Kidney Int Suppl (2011) 2018;8:91–165.
175. Jardine M, Commons RJ, de Zoysa JR, et al. Kidney Health Australia: caring for Australasians with renal impairment guideline recommendations for infection control for haemodialysis units.
Nephrology (Carlton) 2019;24:951–957.
176. Garthwaite E, Reddy V, Douthwaite S, Lines S, Tyerman K, Eccles J. Clinical practice guideline management of blood borne viruses within the haemodialysis unit.
BMC Nephrol 2019;20:388.
177. Foote C, Kotwal S, Gallagher M, Cass A, Brown M, Jardine M. Survival outcomes of supportive care versus dialysis therapies for elderly patients with end-stage kidney disease: a systematic review and meta-analysis.
Nephrology (Carlton) 2016;21:241–253.
178. Wongrakpanich S, Susantitaphong P, Isaranuwatchai S, Chenbhanich J, Eiam-Ong S, Jaber BL. Dialysis therapy and conservative management of advanced chronic kidney disease in the elderly: a systematic review.
Nephron 2017;137:178–189.
179. Smith C, Da Silva-Gane M, Chandna S, Warwicker P, Greenwood R, Farrington K. Choosing not to dialyse: evaluation of planned non-dialytic management in a cohort of patients with end-stage renal failure.
Nephron Clin Pract 2003;95:c40–c46.
180. Joly D, Anglicheau D, Alberti C, et al. Octogenarians reaching end-stage renal disease: cohort study of decision-making and clinical outcomes.
J Am Soc Nephrol 2003;14:1012–1021.
181. Murtagh FE, Marsh JE, Donohoe P, Ekbal NJ, Sheerin NS, Harris FE. Dialysis or not?: a comparative survival study of patients over 75 years with chronic kidney disease stage 5.
Nephrol Dial Transplant 2007;22:1955–1962.
182. Carson RC, Juszczak M, Davenport A, Burns A. Is maximum conservative management an equivalent treatment option to dialysis for elderly patients with significant comorbid disease?
Clin J Am Soc Nephrol 2009;4:1611–1619.
183. Brown MA, Collett GK, Josland EA, Foote C, Li Q, Brennan FP. CKD in elderly patients managed without dialysis: survival, symptoms, and quality of life.
Clin J Am Soc Nephrol 2015;10:260–268.
184. Raman M, Middleton RJ, Kalra PA, Green D. Outcomes in dialysis versus conservative care for older patients: a prospective cohort analysis of stage 5 chronic kidney disease.
PLoS One 2018;13:e0206469.
185. van Loon IN, Goto NA, Boereboom FT, Verhaar MC, Bots ML, Hamaker ME. Quality of life after the initiation of dialysis or maximal conservative management in elderly patients: a longitudinal analysis of the Geriatric assessment in OLder patients starting Dialysis (GOLD) study.
BMC Nephrol 2019;20:108.
186. Verberne WR, Geers AB, Jellema WT, Vincent HH, van Delden JJ, Bos WJ. Comparative survival among older adults with advanced kidney disease managed conservatively versus with dialysis.
Clin J Am Soc Nephrol 2016;11:633–640.
187. Reindl-Schwaighofer R, Kainz A, Kammer M, Dumfarth A, Oberbauer R. Survival analysis of conservative vs. dialysis treatment of elderly patients with CKD stage 5.
PLoS One 2017;12:e0181345.
188. Tam-Tham H, Quinn RR, Weaver RG, et al. Survival among older adults with kidney failure is better in the first three years with chronic dialysis treatment than not.
Kidney Int 2018;94:582–588.
189. Pyart R, Aggett J, Goodland A, et al. Exploring the choices and outcomes of older patients with advanced kidney disease.
PLoS One 2020;15:e0234309.
190. Tam-Tham H, Ravani P, Zhang J, et al. Association of initiation of dialysis with hospital length of stay and intensity of care in older adults with kidney failure.
JAMA Netw Open 2020;3:e200222.
191. Han SS, Park JY, Kang S, et al. Dialysis modality and mortality in the elderly: a meta-analysis.
Clin J Am Soc Nephrol 2015;10:983–993.
192. Kaur A, Davenport A. Hemodialysis for infants, children, and adolescents.
Hemodial Int 2014;18:573–582.
193. Chand DH, Swartz S, Tuchman S, Valentini RP, Somers MJ. Dialysis in children and adolescents: the pediatric nephrology perspective.
Am J Kidney Dis 2017;69:278–286.
194. Salerno AE, Weinstein A, Hanevold C. American Society of Pediatric Nephrology position paper: standard resources required for a pediatric nephrology practice.
J Pediatr 2016;174:254–259.
195. Jones L, Aldridge M. organization and management of a pediatric dialysis program. In: Warady B, Schaefer F, Alexander S, Pediatric dialysis. 2nd ed. New York: Springer; 2012.
196. British Renal Society. The Renal Team: a multi-professional renal workforce plan for adults and children with renal disease. Recommendations of the National Renal Workforce Planning Group. Lichfield (UK): British Renal Society; 2002.
197. UniBritish Columbia Nurses’ Union (BCNU). BCNU Position Statement on mandated nurse-patient ratios. Burnaby (BC): BCNU; 2011.
198. Thomas-Hawkins C, Flynn L, Clarke SP. Relationships between registered nurse staffing, processes of nursing care, and nurse-reported patient outcomes in chronic hemodialysis units.
Nephrol Nurs J 2008;35:123-130,145.